Rapid health technology assessment of calcitonin in the treatment of postmenopausal osteoporosis
- VernacularTitle:降钙素治疗绝经后骨质疏松症的快速卫生技术评估
- Author:
Zihui ZHENG
1
;
Feng GAO
2
;
Yatong ZHANG
1
;
Zinan ZHAO
1
;
Huijie PAN
3
;
Liwei JI
1
;
Xin HU
1
;
Pengfei JIN
4
Author Information
1. Dept. of Pharmacy，Beijing Hospital/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital ），Beijing 100730，China;National Center of Gerontology/ Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730，China
2. Dept. of Health Service，the Guard Bureau of the Joint Staff Department of Chinese PLA，Beijing 100017，China
3. National Center of Gerontology/ Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730，China;Dept. of Laboratory，Beijing Hospital，Beijing 100730，China
4. Dept. of Pharmacy，Beijing Hospital/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital ），Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
calcitonin;
postmenopausal osteoporosis;
health economics;
rapid health technology assessment
- From:
China Pharmacy
2022;33(21):2654-2659
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE According to the rapid Health Technology Assessment （HTA） for postmenopausal osteoporosis （PMOP），To evaluate the efficacy ，safety and economy of calcitonin in the treatment of PMOP ，and provide evidence -based medical evidence for clinical drug decision . METHODS Retrieved from the Cochrane Library ，PubMed，Embase，CNKI，Wanfang database，CBM and HTA official website ，systematic review/meta -analysis，pharmacoeconomics research and HTA reports about calcitonin in the treatment of PMOP were retrieved from the inception to Sept . 30th，2022. Two researchers independently carried out screening ，data extraction and quality evaluation ，and analyzed the data results descriptively . RESULTS A total of 18 studies were included ，including 12 SR/meta-analysis and 6 economic studies ，and no HTA report was retrieved . In terms of effectiveness ， the results of the included studies were basically consistent ：calcitonin had a certain advantage in reducing the incidence of vertebral fracture compared with calcium and lasoxifene alone ，but did not show clinical advantage compared with other positive drugs . In terms of reducing the incidence of non -vertebral fractures ， calcitonin had some advantages ，compared with calcium al one and raloxifene ，but did not show clinical advantage compared with other positive drugs . In terms of improving bone mineral density（BMD），only 2 studies showed that calcitonin had a certain advantage over calcium but no advantage was observed compared with other positive drugs . In terms of improving non - vertebral BMD ，only 1 study showed that calcitonin combined with calcium had certain advantages compared with calcium alone in improving femoral BMD ，but there was no advantage compared with other positive drugs . In terms of lowering bone pain scores ， both included studies demonstrated short -term benefit of nasal calcitonin in reducing acute pain was found in patients with vertebral fractures，but not in patients with chronic pain . In terms of safety ，the three included studies showed that calcitonin caused mild adverse reactions compared with other positive drugs ，but there was a risk of malignant tumors after long -term use . In terms of economy，only 1 study showed the use of nasal calcitonin in the treatment of PMOP had more economic advantages than no treatment or etidronate . CONCLUSIONS Calcitonin has a certain effect on reducing acute pain in patients with PMOP vertebral fracture，and its safety needs further investigation . No obvious economic advantage has been found .
